New antibody drug shows promise for vitiligo in early trial

NCT ID NCT04338581

Completed Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2a trial tested an experimental drug called AMG 714 in 60 adults with vitiligo, a condition that causes white patches on the skin. The drug works by blocking a protein called IL-15, which may play a role in the disease. Participants received either AMG 714 or a placebo, and some also received light therapy if their skin didn't improve enough. The main goal was to see if the drug could reduce facial vitiligo by at least 35% after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMG 714 (an antibody that blocks IL-15)
What this could lead to: If it works, this could point toward a new treatment option for vitiligo that helps reduce white patches on the skin.
What could go wrong: This is a small, early-phase trial with only 60 participants. The drug may not work better than placebo, and side effects are possible. Results may not apply to everyone with vitiligo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VITILIGO

Contacts and locations

Locations

Henry Ford Health System

Detroit, Michigan, 48202, United States
Northwell Health

Lake Success, New York, 11042, United States
Tufts Medical Center: Department of Dermatology

Boston, Massachusetts, 02111, United States
University of California Davis Health System: Department of Dermatology

Sacramento, California, 95816, United States
University of California, Irvine: Department of Dermatology

Irvine, California, 92697, United States
University of Massachusetts Medical School

Worcester, Massachusetts, 01605, United States
Yale University School of Medicine: Department of Dermatology

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.